Type Whole antibody Target EGFR Routes of
administration Intravenous infusion | Source Human Trade names Portrazza | |
AHFS/Drugs.com Multum Consumer Information | ||
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR). The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC). It was counterproductive in non-squamous non-small-cell lung carcinoma.
References
Necitumumab Wikipedia(Text) CC BY-SA